| P/E (FY) | — | Sales (TTM) | $113.0M |
| Earnings (TTM) | -$75.1M | ROE | −18.30% |
| Net Margin | −59.76% | ROIC | −40.02% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −33.29% |
OraSure Technologies develops, manufactures, and sells diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. Its products include OraQuick rapid and self-tests for HIV, HCV, syphilis, and Ebola, the InteliSwab COVID-19 tests, the SickleSCAN test, Intercept drug testing systems, and saliva alcohol tests. The company also offers genomic collection products under the Oragene and ORAcollect brands and Colli-Pee collection devices.
| Market Cap | $276.8M | Trading Days | 5292 |
| 52W High | 4.58 |
| 52W Low | 2.08 |
| % Off High | −12.23% |
| YTD | 66.12% | 1Y | 20.00% |
| 3Y | −13.17% | 5Y | −64.39% |
| 10Y | −39.00% | Since incept. (ann.) | −4.72% |
US 68% · Africa 21% · Europe 6% · Other Foreign Countries 5%
| Ann. Volatility (1Y) | 48.33% | Ann. Volatility (3Y) | 51.36% |
| Sharpe (1Y) | 0.62 | Sharpe (3Y) | 0.16 |
| Max Drawdown (1Y) | −39.37% | Max Drawdown (3Y) | −74.73% |
| Beta (3Y, vs SPY) | 1.20 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TLSI | TriSalus Life Sciences, Inc. | $265.9M | — |
| SGHT | Sight Sciences, Inc. | $288.4M | — |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | $264.7M | — |
| PROF | Profound Medical Corp. | $263.4M | 5.1 |
| PSTV | PLUS THERAPEUTICS, INC. | $292.5M | — |
| OBIO | Orchestra BioMed Holdings, Inc. | $231.1M | — |
| CARL | CARLSMED, INC. | $334.6M | — |
| UTMD | UTAH MEDICAL PRODUCTS INC | $225.9M | 20.4 |
| EMBC | Embecta Corp. | $213.0M | 2.2 |
| MOBI | Mobia Medical, Inc. | $370.1M | — |
| ANIK | Anika Therapeutics, Inc. | $201.6M | — |
| INFU | InfuSystem Holdings, Inc | $200.2M | 32.0 |
